AstraZeneca CEO Receives Vested Shares Under Performance Plan

AstraZeneca ( (GB:AZN) ) has shared an announcement.

AstraZeneca announced the vesting of ordinary shares to CEO Pascal Soriot under the AstraZeneca Performance Share Plan. The award, granted in 2020, vested after a three-year performance period and a two-year holding period, resulting in 97% of the award vesting. This transaction reflects AstraZeneca’s commitment to rewarding its leadership based on performance, potentially impacting the company’s executive compensation strategy and stakeholder perceptions.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £14500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca is well-positioned in the pharmaceutical industry with robust financials and promising corporate initiatives. The strong earnings call and strategic corporate events support a long-term positive outlook. However, short-term technical weaknesses and valuation concerns temper the score.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Average Trading Volume: 2,772,888

Technical Sentiment Signal: Hold

Current Market Cap: £160.9B

Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.